Verner Clinic of Dermatology and Aesthetics, Tel Aviv, Israel.
Department of Dermatology and Regenerative Medicine, University of Rome " Guglielmo Marconi ", Rome, Italy.
Dermatol Ther. 2020 Nov;33(6):e14002. doi: 10.1111/dth.14002. Epub 2020 Jul 26.
Dermatochalasis (DC) is part of the aging process of the eyelids, characterized by lax, redundant, and overhanging excess eyelid skin. Mostly, it is treated by surgical blepharoplasty. Lately alternative nonsurgical blepharoplasty technologies have been introduced. In this study, we evaluated the efficacy and safety of a novel noninvasive RF microplasma technology for upper eyelid DC. A prospective single center study included 17 patients with moderate to severe upper eyelid DC. Subjects were treated by controlled micro-plasma sparks via a single tip leading to superficial ablation and coagulation at the treatment area. One to three treatment sessions at 2 months interval were performed. Three blinded observers evaluated the photographs taken at baseline and at 6 to 8 months follow-up visit following the final treatment session. Treatment efficacy was assessed using a 4-point grading scale. Seven out of 17 patients (41%) treated for DC by the single microplasma spark exhibited a 2 grade improvement on a 4 point DC scale. 10 out of 17 (59%) patients showed a single grade improvement on a 4 point DC scale. No adverse side effects were observed. Noninvasive ablative microplasma may offer safe and effective therapy for upper eyelid DC.
皮肤松弛症 (DC) 是眼睑老化过程的一部分，其特征为松弛、多余和悬垂的多余眼睑皮肤。大多数情况下，它通过手术眼睑成形术进行治疗。最近，已经引入了替代的非手术眼睑成形术技术。在这项研究中，我们评估了一种新型非侵入性 RF 微等离子体技术治疗上眼睑 DC 的疗效和安全性。一项前瞻性单中心研究纳入了 17 名患有中重度上眼睑 DC 的患者。通过单个尖端控制微等离子体火花对治疗区域进行浅表消融和凝固，对受试者进行治疗。在 2 个月的间隔内进行 1 到 3 次治疗。在最后一次治疗后 6 到 8 个月的随访中，三位盲法观察者评估了基线和随访照片。使用 4 分制评分评估治疗效果。在接受单次微等离子体火花治疗的 17 名 DC 患者中，有 7 名（41%）在 4 分 DC 评分上改善了 2 级。17 名患者中的 10 名（59%）在 4 分 DC 评分上改善了 1 级。未观察到不良反应。非侵入性消融性微等离子体可能为上眼睑 DC 提供安全有效的治疗。
